

Telefax



Boehringer
Ingelheim RECEIVED
CENTRAL FAX CENTER

DEC 01 2005

TO: USPTO
 DATE: December 1, 2005
 Fax Number: (571) 273-8300
 Number: (703) 308-9723
 Total Number of pages: 3 (including cover sheet)

Boehringer Ingelheim
Corporation

RE: Response to Office Action
 Serial Number: 10/807,023
 Confirmation Number: 2248
 Filing Date: 3/23/2004
 First Inventor: CHEN, S., et. al.
 Attorney Docket Number: 9/279

Philip I. Datlow
 Telephone (203) 798-4542
 Telefax (203) 798-4408
 E-Mail pdatlow@rdg.boehringer-
 ingelheim.com
 900 Ridgebury Rd/P.O. Box 368
 Ridgefield, CT 06877-0368

Dear Sir:

Please find transmitted herewith a Response to the Office Action dated November 1, 2005 for the above-identified application.

The Commissioner is hereby authorized to charge or credit any fee which may be required to Deposit Account No. 02-2955.

Respectfully Submitted,


 Philip I. Datlow
 Reg. No. 41,482

Certificate of Transmission under 37 CFR 1.8
 I hereby certify that this correspondence is being
 facsimile transmitted to the United States Patent
 and Trademark Office to Fax No. (571) 273-8300
 on December 1, 2005


 Philip I. Datlow, Reg. No. 41,482

RESPONSE
US APPLN. NO. 10/807,023

RECEIVED
CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 01 2005

Aplication of: CHEN, S., et. al.) Art Unit: 1654
Serial No.: 10/807,023) Examiner: Kosar, Andrew D.
Conf. No.: 2248
Filed: 03/23/2004
For: Pharmaceutical Compositions for Hepatitis C Viral Protease Inhibitors
Docket No.: 9/279

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE

Sir:

This is in response to the Office Action dated November 1, 2005, setting forth a 1 month period for reply. At page 2 of the office action, the examiner sets forth a restriction requirement in 4 groups:

- I. Claims 1-27, drawn to a composition comprising compounds of formula (I)
- II. Claim 28, drawn to a method of manufacturing a composition of claim 1
- III. Claim 29, drawn to a method of inhibiting HCV replication
- IV. Claim 30, drawn to treating HCV infection in a mammal

At pages 3-4, the examiner also requires an election of species with respect to the pharmaceutical composition, i.e. a single pharmaceutical composition where each element (a) to (g) is fully defined, and any claims readable thereon.

In response, Applicants herein elect Group I, with Formulation #3 (at page 39) as the elected species. Claims 1-13 and 15-30 read upon this elected species, or its method of use or method of synthesis. This election is made with traverse.

Applicants traverse the election of species requirement. Applicants submit that, at the very least, the compounds of formula (I) as depicted in claim 1 constitute a proper Markush Group of compounds as they all share a common substantial structural core and all share a common utility as HCV NS3 protease inhibitors useful for treating HCV infection. In addition, all the claimed


RESPONSE
US APPLN. NO. 10/807,023

pharmaceutical compositions are related by being compositions of the compounds of formula (I) and having the components in the amounts indicated in claim 1. All the compositions contain an amine or mixture of amines in amounts indicated, a base or mixture of bases in amounts indicated and one or more oils, as specified for components (b) to (d), and all optionally contain one or more solvents, polymers and/or surfactants as specified for components (e) to (g). Thus, Applicants respectfully submit that the claimed subject matter is sufficiently related to be properly presented and examined in a single application. Accordingly, Applicants elect a single disclosed composition species herein on the understanding that this is done only to facilitate initial search and examination, but that this application will be generically examined in accordance with the USPTO's Markush Practice as outline in MPEP 803.02 in the event that the elected species is found to be patentable.

Applicants appreciate the Examiner's acknowledgment (at pgs. 4-5 of the Office Action) that the USPTO's Rejoinder Practice (MPEP 821.04) is applicable to the present application. In the event that the product claims of Group I are found to be allowable, Applicants request that the process (method) claims of Groups II, III and IV be rejoined in the examination under Rejoinder Practice since all these process claims depend from the product claims of Group I.

In view of the above remarks, Applicants respectfully submit that this application is now in condition for early examination. If any points remain at issue which can best be resolved by way of a telephonic or personal interview, the Examiner is kindly requested to contact the undersigned attorney at the telephone number listed below.

Respectfully submitted,



Philip I. Datlow
 Attorney for Applicant(s)
 Reg. No. 41,482

Patent Department
 Boehringer Ingelheim Corp.
 900 Ridgebury Road
 P.O. Box 368
 Ridgefield, CT 06877
 Tel: (203) 798-4542
 Date: December 1, 2005

Certificate of Transmission
 I hereby certify that this correspondence is being facsimile
 transmitted to the US Patent and Trademark Office to:

Fax # (571) 273-8300 on December 1, 2005.



Philip I. Datlow, Reg. No. 41,482